Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rocatinlimab in adults with prurigo nodularis
jRCT2031240328Phase 3Suspended
- Sponsor
- Amgen
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of rocatinlimab in prurigo nodularis (PN) (4 arms), sponsored by Amgen. Primary endpoint: Number of participants achieving reduction from baseline in weekly average of daily itch score at Week 24. Started Dec 2024; status: suspended.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2031240328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240328.